Safety and Effectiveness of Amphotericin B Deoxycholate for the Treatment of Visceral Leishmaniasis in Uganda.

Hdl Handle:
http://hdl.handle.net/10144/23215
Title:
Safety and Effectiveness of Amphotericin B Deoxycholate for the Treatment of Visceral Leishmaniasis in Uganda.
Authors:
Mueller, Y; Nguimfack, A; Cavailler, P; Couffignal, S; Rwakimari, J B; Loutan, L; Chappuis, F
Journal:
Annals of Tropical Medicine and Parasitology
Abstract:
Between September 2003 and April 2004, the supply of antimonial drugs to Amudat Hospital, in north-eastern Uganda, was interrupted and all cases of visceral leishmaniasis presenting at the hospital could only be treated with amphotericin B deoxycholate (AmB). This allowed the safety and effectiveness of the AmB to be evaluated, in comparison with an historical cohort of patients treated, at the same hospital, with meglumine antimoniate (Sb(V)). Demographic and clinical data were collected before and after treatment. Adverse effects were recorded passively in all the subjects, and actively, using a standardized questionnaire, in a sub-group of the patients given AmB. The in hospital case-fatality 'rates' were 4.8% [95% confidence interval (CI) = 2.4%-8.8%] among the 210 patients treated with AmB and 3.7% (CI = 1.4%-7.9%) among the 161 patients treated with Sb(V) (P>0.20). Adverse effects requiring treatment interruption were rare in both cohorts. Treatment failures (i.e. non-responses or relapses) were observed in 2.9% (CI = 1.2%-6.4%) of the patients treated with AmB and 1.2% (CI = 0.1%-4.4%) of the patients treated with Sb(V) (P>0.20). For the treatment of visceral leishmaniasis in Uganda, AmB therefore had a similar effectiveness and safety profile to that of meglumine antimoniate.
Affiliation:
Médecins Sans Frontières, Swiss Section, Rue de Lausanne 78, 1202 Geneva, Switzerland. yolanda.mueller@freesurf.ch
Publisher:
Maney Publishing
Issue Date:
Jan-2008
URI:
http://hdl.handle.net/10144/23215
DOI:
10.1179/136485908X252142
PubMed ID:
18186974
Additional Links:
http://www.maney.co.uk/journals/atmp
Language:
en
ISSN:
0003-4983
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorMueller, Y-
dc.contributor.authorNguimfack, A-
dc.contributor.authorCavailler, P-
dc.contributor.authorCouffignal, S-
dc.contributor.authorRwakimari, J B-
dc.contributor.authorLoutan, L-
dc.contributor.authorChappuis, F-
dc.date.accessioned2008-04-14T11:09:42Z-
dc.date.available2008-04-14T11:09:42Z-
dc.date.issued2008-01-
dc.identifier.citationSafety and Effectiveness of Amphotericin B Deoxycholate for the Treatment of Visceral Leishmaniasis in Uganda. 2008, 102 (1):11-9 Ann. Trop. Med. Parasitol.en
dc.identifier.issn0003-4983-
dc.identifier.pmid18186974-
dc.identifier.doi10.1179/136485908X252142-
dc.identifier.urihttp://hdl.handle.net/10144/23215-
dc.description.abstractBetween September 2003 and April 2004, the supply of antimonial drugs to Amudat Hospital, in north-eastern Uganda, was interrupted and all cases of visceral leishmaniasis presenting at the hospital could only be treated with amphotericin B deoxycholate (AmB). This allowed the safety and effectiveness of the AmB to be evaluated, in comparison with an historical cohort of patients treated, at the same hospital, with meglumine antimoniate (Sb(V)). Demographic and clinical data were collected before and after treatment. Adverse effects were recorded passively in all the subjects, and actively, using a standardized questionnaire, in a sub-group of the patients given AmB. The in hospital case-fatality 'rates' were 4.8% [95% confidence interval (CI) = 2.4%-8.8%] among the 210 patients treated with AmB and 3.7% (CI = 1.4%-7.9%) among the 161 patients treated with Sb(V) (P>0.20). Adverse effects requiring treatment interruption were rare in both cohorts. Treatment failures (i.e. non-responses or relapses) were observed in 2.9% (CI = 1.2%-6.4%) of the patients treated with AmB and 1.2% (CI = 0.1%-4.4%) of the patients treated with Sb(V) (P>0.20). For the treatment of visceral leishmaniasis in Uganda, AmB therefore had a similar effectiveness and safety profile to that of meglumine antimoniate.en
dc.language.isoenen
dc.publisherManey Publishingen
dc.relation.urlhttp://www.maney.co.uk/journals/atmpen
dc.rightsArchived on this site with the kind permission of Maney Publishingen
dc.titleSafety and Effectiveness of Amphotericin B Deoxycholate for the Treatment of Visceral Leishmaniasis in Uganda.en
dc.contributor.departmentMédecins Sans Frontières, Swiss Section, Rue de Lausanne 78, 1202 Geneva, Switzerland. yolanda.mueller@freesurf.chen
dc.identifier.journalAnnals of Tropical Medicine and Parasitologyen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.